benanserin hydrochloride | 525-02-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: benanserin hydrochloride
• 英文别名: 2-(1-benzyl-5-methoxy-2-methyl-1H-indol-3-yl)ethanaminium chloride；MLS001030162；BAS；2-(1-benzyl-5-methoxy-2-methyl-indol-3-yl)-ethylamine; hydrochloride；[2-(1-benzyl-5-methoxy-2-methyl-1H-indol-3-yl)ethyl]amine hydrochloride；2-(1-Benzyl-5-methoxy-2-methyl-indol-3-yl)-aethylamin; Hydrochlorid；2-(1-benzyl-5-methoxy-2-methylindol-3-yl)ethanamine;hydron;chloride
• CAS: 525-02-0
• 化学式: C₁₉H₂₂N₂O*ClH
• 分子量: 330.857
• InChiKey: HEVSQLIUCMHBPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.93
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  40.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] TRYPTAMINE-DERIVED COMPOUNDS AS ANTIBACTERIAL AGENTS<br/>[FR] COMPOSÉS DÉRIVÉS DE LA TRYPTAMINE UTILISÉS EN TANT QU'AGENTS ANTIBACTÉRIENS
  申请人：UNIV LIEGE

  公开号：WO2011060976A1

  公开（公告）日：2011-05-26

  The present invention relates to a compound according to formula I, a pharmaceutically acceptable salt and/or N-oxide thereof for use as an antibacterial agent.

  本发明涉及一种符合公式I的化合物，其药学上可接受的盐和/或N-氧化物，用作抗菌剂。
• ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF
  申请人：Fang Bingliang

  公开号：US20090286847A1

  公开（公告）日：2009-11-19

  Embodiments of the present invention provide for methods and compositions comprising an Oncorasin, such as 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1) and/or its analogs or derivatives.

  本发明的实施例提供了一种包括Oncorasin的方法和组合物，例如1-[(4-氯苯基)甲基]-1H-吲哚-3-羧醛（oncrasin-1）及/或其类似物或衍生物。
• COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS
  申请人：Acadia Pharmaceuticals Inc.

  公开号：EP2134330A2

  公开（公告）日：2009-12-23
• COMBINATION OF PIMAVANSERIN AND RISPERIDONE FOR THE TREATMENT OF PSYCHOSIS
  申请人：PETERS Perry

  公开号：US20130143901A1

  公开（公告）日：2013-06-06

  Combinations of 5-HT2A inverse agonists or antagonists such as pimavanserin with antipsychotics such as risperidone are shown to induce a rapid onset of antipsychotic action and increase the number of responders when compared to therapy with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects. The combinations are also effective at decreases the incidence of weight gain and increased glucose or prolactin levels caused by the antipsychotic.
• US8883841B2
  申请人：——

  公开号：US8883841B2

  公开（公告）日：2014-11-11